All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The SOT Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the SOT Hub cannot guarantee the accuracy of translated content. The SOT Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Solid Organ Transplantation Hub is an independent medical education platform, sponsored by Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View solid organ transplantation content recommended for you
Results from a mechanistic substudy of the randomized HOPE-NMP trial (NCT04644744), evaluating hepatic and systemic immune responses across preservation strategies in recipients of extended-criteria donor livers after brain death (N = 47), were published in Gut by Lurje et al. Patients received grafts preserved by static cold storage (SCS; n = 11), hypothermic oxygenated perfusion (HOPE; n = 24), or normothermic machine perfusion (NMP; n = 12).
Key data: Both HOPE- and NMP-perfused grafts showed reduced neutrophil infiltration during early ischemia-reperfusion injury (IRI) and attenuated expression of myeloid activation-associated markers compared with SCS grafts. HOPE recipients had lower systemic relative neutrophil proportions than SCS recipients on postoperative Day 3 (42.7% vs 80.7%; adjusted p = 0.040) and Day 7 (39.4% vs 71.8%; adjusted p = 0.040), with faster lymphocyte recovery after HOPE than after SCS or NMP. Systemic neutrophil expansion after transplantation correlated with markers of hepatocellular injury, and neutrophil counts were higher in patients who developed early allograft dysfunction (EAD). Hepatic immune cell localization remained similar across preservation strategies.
Key learning: In this mechanistic substudy, HOPE and NMP were associated with attenuated hepatic and systemic innate immune activation following liver transplantation, whereas only HOPE was associated with faster peripheral lymphocyte recovery. These exploratory findings suggest immunomodulation as a mechanism of machine perfusion; however, further validation in larger cohorts is required.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
Which of the following additional evidence do you think would have the greatest impact on clinicians’ choice to adopt ECP in SOT?